The concept of using photoactivated chromophores for corneal cross-linking (PACK-CXL) as a weapon against infectious keratitis
is compelling. The evidence suggests that PACK-CXL could have a dramatic impact on a major cause of global blindness… but only if the expensive, bulky technology (and the requirement for a corneal surgeon in a sterile operating theater) can be overcome. One company may have the answer.
